| human | Q5 |
| P496 | ORCID iD | 0000-0002-2474-1378 |
| P735 | given name | Kristiina | Q19858700 |
| Kristiina | Q19858700 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q38325322 | 7q deletion mapping and expression profiling in uterine fibroids. |
| Q36021406 | 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q33938690 | A 4-bp deletion in the Birt-Hogg-Dubé gene (FLCN) causes dominantly inherited spontaneous pneumothorax |
| Q37218535 | A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer |
| Q33663091 | A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer |
| Q30329947 | A Novel mutation in the FSH receptor inhibiting signal transduction and causing primary ovarian failure. |
| Q42676622 | A combined analysis of genome-wide association studies in breast cancer |
| Q47723045 | A founder mutation in CERKL is a major cause of retinal dystrophy in Finland |
| Q34744122 | A genome wide meta-analysis study for identification of common variation associated with breast cancer prognosis |
| Q34613513 | A genome-wide association scan on estrogen receptor-negative breast cancer |
| Q29417036 | A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q36435849 | A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. |
| Q47140243 | A missense mutation in SLC26A3 is associated with human male subfertility and impaired activation of CFTR. |
| Q36152991 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers |
| Q28178473 | A novel sequence variation in the transactivation regulating domain of the androgen receptor in two infertile Finnish men |
| Q35870483 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients |
| Q114182800 | A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients |
| Q36113106 | ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer |
| Q33254230 | ATM variants and cancer risk in breast cancer patients from Southern Finland |
| Q37417780 | AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study |
| Q61970237 | Abstract 3274: SNP-SNP interaction analyses of NQO1 and NF-κB signaling pathway genes on breast cancer survival and treatment outcome |
| Q59273292 | Altered Expression of MLH1, MSH2, and MSH6 in Predisposition to Hereditary Nonpolyposis Colorectal Cancer |
| Q33327370 | An information-theoretic analysis of genetics, gender and age in cancer patients |
| Q35618307 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers |
| Q53252110 | Analysis of KLHDC8B in familial nodular lymphocyte predominant Hodgkin lymphoma. |
| Q57567427 | Analysis of a Finnish family confirms RHBDF2 mutations as the underlying factor in tylosis with esophageal cancer |
| Q35681656 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis |
| Q57567504 | Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer |
| Q35242849 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers |
| Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q33828680 | Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival |
| Q91271723 | Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness |
| Q36178189 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. |
| Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
| Q99609984 | Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer |
| Q34801008 | Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
| Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q57274795 | BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q36643102 | Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families |
| Q35083362 | Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors |
| Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
| Q114182645 | Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores |
| Q46610600 | Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q36245422 | Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases |
| Q35683548 | Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications |
| Q57305977 | Breast-Cancer Risk in Families With Mutations in PALB2 |
| Q34148873 | Breast-cancer risk in families with mutations in PALB2 |
| Q34396517 | CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma |
| Q41611265 | CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population |
| Q47236534 | CHEK2 variant I157T may be associated with increased breast cancer risk |
| Q92005489 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families |
| Q34963894 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q33677756 | Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility |
| Q96962174 | Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
| Q37331451 | Chorionic gonadotropin beta-gene variants are associated with recurrent miscarriage in two European populations |
| Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q34394665 | Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction |
| Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q33742096 | Common genetic variants and modification of penetrance of BRCA2-associated breast cancer |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q33323243 | Comprehensive analysis of NuMA variation in breast cancer |
| Q95939223 | Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer |
| Q57266620 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer |
| Q45793899 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q28388475 | Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations |
| Q46778846 | Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer |
| Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q102384990 | Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing |
| Q46828694 | Distinct expression profile in fumarate-hydratase-deficient uterine fibroids |
| Q61841363 | Do mitochondrial mutations cause recurrent miscarriage? |
| Q38451178 | Does the Y chromosome have a role in Müllerian aplasia? |
| Q46750068 | Effect of oral and transdermal hormone therapy on hyaluronic acid in women with and without a history of intrahepatic cholestasis of pregnancy |
| Q44048872 | Effects of follicle-stimulating hormone (FSH) and human chorionic gonadotropin in individuals with an inactivating mutation of the FSH receptor |
| Q38605081 | Epigenetics and assisted reproductive technologies |
| Q44380443 | Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment |
| Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
| Q35173572 | Evaluation of SHOX copy number variations in patients with Müllerian aplasia |
| Q53065212 | Evaluation of the RHINO gene for breast cancer predisposition in Finnish breast cancer families. |
| Q51773668 | Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. |
| Q57266727 | Evaluation ofRAD50 in familial breast cancer predisposition |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q34408752 | Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer |
| Q39544580 | Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma |
| Q37394076 | FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome |
| Q42683589 | FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population |
| Q53487694 | Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. |
| Q48212258 | Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy |
| Q37307305 | Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls |
| Q40391765 | Fever from the cold--familial cold autoinflammatory syndrome |
| Q74620385 | Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q43931522 | Functional characterization of the human FSH receptor with an inactivating Ala189Val mutation |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q38627916 | Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication |
| Q38467584 | Genetic features of the X chromosome affect pubertal development and testicular degeneration in adolescent boys with Klinefelter syndrome |
| Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q35022825 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q35029543 | Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer |
| Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
| Q36102997 | Genetics and assisted reproduction technology |
| Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q29417100 | Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer |
| Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
| Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
| Q34173446 | Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families |
| Q24595882 | Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics |
| Q33901605 | Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development |
| Q96432094 | Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk |
| Q34115940 | Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer |
| Q34158129 | Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome |
| Q57306210 | Glycodelin expression associates with differential tumour phenotype and outcome in sporadic and familial non-BRCA1/2 breast cancer patients |
| Q35382206 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers |
| Q57471595 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q36072197 | Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment |
| Q33330850 | Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics |
| Q114182839 | High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome |
| Q24796660 | Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q35541663 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q64039792 | Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans |
| Q35035334 | Ingraft chimerism in lung transplantation--a study in a porcine model of obliterative bronchiolitis |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q50165058 | Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. |
| Q57671334 | Large genomic rearrangements and germline epimutations in Lynch syndrome |
| Q92313654 | Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q73152768 | Long CAG repeats in the AR gene are not associated with infertility in Finnish males |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q31043651 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q92860654 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers |
| Q49252742 | Meta-analysis of three genome-wide association studies identifies two loci that predict survival and treatment outcome in breast cancer. |
| Q54379833 | Methylation of H19 and its imprinted control region (H19 ICR1) in Müllerian aplasia. |
| Q34079217 | MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
| Q33628755 | Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q57567547 | Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer |
| Q49024646 | Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. |
| Q46567991 | NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer |
| Q57306207 | NQO1 expression correlates inversely with NFκB activation in human breast cancer |
| Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
| Q44360443 | Nitric oxide metabolites in cervical fluid during pregnancy: further evidence for the role of cervical nitric oxide in cervical ripening |
| Q37237352 | No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q46958521 | No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome. |
| Q37308596 | No evidence that GATA3 rs570613 SNP modifies breast cancer risk |
| Q37079859 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing |
| Q57306224 | No germline FH mutations in familial breast cancer patients |
| Q46320481 | Obstetric and neonatal outcome after oocyte donation in 106 women with Turner syndrome: a Nordic cohort study |
| Q41961679 | Other short opinions/comments on moderate/low cancer genetic risk markers in medical practice and the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis a |
| Q89927576 | Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D |
| Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q35737888 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
| Q37307937 | Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q37131918 | Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families |
| Q97524107 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants |
| Q36071595 | Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy |
| Q45102073 | Postmenopausal estrogen therapy and serum estradiol fatty acid esters in women with and without previous intrahepatic cholestasis of pregnancy |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q48872572 | Pregnancies after oocyte donation in women with ovarian failure caused by an inactivating mutation in the follicle stimulating hormone receptor. |
| Q46868740 | Prognostic role of HuR in hereditary breast cancer |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q35502165 | RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families |
| Q36009422 | RAD51B in Familial Breast Cancer |
| Q57306209 | RAD51C is a susceptibility gene for ovarian cancer |
| Q55671434 | Recessively inherited right atrial isomerism caused by mutations in growth/differentiation factor 1 (GDF1) |
| Q92710828 | Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q24810584 | Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families |
| Q37300024 | Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. |
| Q36545934 | SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival |
| Q57754538 | Screening of HELQ in breast and ovarian cancer families |
| Q38475529 | Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy |
| Q38458167 | Sex chromosome characteristics and recurrent miscarriage |
| Q38451303 | Study of p53 gene mutations and placental expression in recurrent miscarriage cases |
| Q38603684 | Surrogacy: outcomes for surrogate mothers, children and the resulting families-a systematic review |
| Q21202853 | TBX6, LHX1 and copy number variations in the complex genetics of Müllerian aplasia |
| Q33566957 | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer |
| Q49817640 | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. |
| Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
| Q35781316 | The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients |
| Q46041916 | The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype |
| Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
| Q45222336 | The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes |
| Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
| Q57306205 | Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer |
| Q35889659 | Variants on the promoter region of PTEN affect breast cancer progression and patient survival |
| Q38470113 | Variations of the Amnionless gene in recurrent spontaneous abortions |
| Q95535012 | [Fetal diagnosis from the mother's blood--noninvasive screening of chromosomal aberrations] |
Search more.